ACADIA Pharmaceuticals Inc. (ACAD) | Investment Case

1. Company Snapshot

1.a. Company Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's.

ACADIA Pharmaceuticals Inc.was founded in 1993 and is headquartered in San Diego, California.

Show Full description

1.b. Last Insights on ACAD

ACADIA Pharmaceuticals Inc.'s recent performance has been driven by several positive factors. The company's Q3 earnings beat estimates, with quarterly earnings of $0.26 per share, surpassing the Zacks Consensus Estimate of $0.14 per share. Additionally, Envestnet Asset Management Inc. and Atria Investments Inc. have increased their stakes in the company, with Envestnet acquiring an additional 19,975 shares and Atria adding 4,574 shares. Furthermore, the company is set to participate in Citi's 2025 Global Healthcare Conference, and Braidwell has taken a new position in the company, valued at approximately $50.8 million.

1.c. Company Highlights

Last Price	27.44
Change Percentage	3.35%
Open	26.86
Previous Close	26.55
Market Cap ( Millions)	4642
Volume	2104617
Year High	27.61
Year Low	13.4
M A 50	22.64
M A 200	21.07

FCF Yield	4.03%
Dividend Yield	0.00%
ROE	30.67%
Debt / Equity	6.85%
Net Debt / EBIDTA	-185.65%
Price To Book	5.6
Price Earnings Ratio	20.73
Price To FCF	24.81
Price To sales	4.56
EV / EBITDA	41.81

2. ACADIA Pharmaceuticals' Q3 2025 Earnings: Strong Revenue Growth and Pipeline Advancements

ACADIA Pharmaceuticals reported total revenues of $278.6 million for Q3 2025, representing an 11% increase from the same period last year. The company's net sales of DAYBUE reached $101.1 million, while NUPLAZID generated $177.5 million in net sales, marking its strongest sales quarter ever. The earnings per share (EPS) came in at $0.26, beating analyst estimates of $0.14. The company's cash position stood at $847 million at the end of Q3 2025.

Publication Date: Nov -09

                                    📋 Highlights
                                    Total Revenues::
                                                $278.6 million in Q3 2025, a 11% increase YoY.
DAYBUE Sales::
                                                Generated $101.1 million in net sales with over 1,000 global patients.
NUPLAZID Performance::
                                                Record $177.5 million in net sales, with 30% field force expansion planned.
Cash Reserves::
                                                Ended Q3 with $847 million, up from $762 million in Q2 2025.
Guidance Updates::
                                                Raised NUPLAZID 2025 guidance to $685–$695 million and DAYBUE to $385–$400 million.

                                

Revenue Breakdown and Guidance Update

The revenue growth was driven by the strength of ACADIA's commercial portfolio, with both DAYBUE and NUPLAZID contributing to the increase. The company has updated its full-year 2025 guidance, raising the lower end of the range for NUPLAZID to $685 million to $695 million and narrowing the guidance range for DAYBUE to $385 million to $400 million. The updated guidance reflects the company's strong performance and outlook.

Pipeline Advancements and Future Growth

ACADIA's pipeline continues to represent a significant opportunity for future growth, with several ongoing studies and anticipated readouts. The company has initiated a Phase II study for ACP-204 in Lewy body dementia psychosis and a Phase III study of trofinetide in Japan. The company expects to report results from four Phase II or Phase III studies between now and the end of 2027. As Elizabeth Thompson mentioned, "We are dedicated to advancing our robust pipeline, and we look forward to the 4 major readouts expected in 2026 and 2027."

Valuation and Growth Prospects

Analysts estimate ACADIA's revenue growth at 11.0% for next year. The company's current valuation metrics include a P/E Ratio of 17.05, P/S Ratio of 3.74, and EV/EBITDA of 33.97. The ROE stands at 30.67%, indicating a strong return on equity. These metrics suggest that the market has priced in a certain level of growth, but the company's pipeline advancements and revenue growth prospects may provide further upside potential.

Commercial Strategy and Investment

ACADIA is making strategic investments to drive growth, including a field force expansion for NUPLAZID. The company is adding 50 customer-facing representatives to its field force, with the goal of reaching new prescribers and growing its share in the PDP population. As Tom Garner mentioned, "We believe that the NUPLAZID fundamentals are strong, and the market opportunity is substantial, with a differentiated product profile, accelerating demand indicators, and targeted investments in our commercial model."

3. NewsRoom

Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality

Dec -04

Source: seekingalpha.com

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?

Dec -04

Source: fool.com

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec -02

Source: seekingalpha.com

Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

Nov -20

Source: businesswire.com

Envestnet Asset Management Inc. Raises Holdings in ACADIA Pharmaceuticals Inc. $ACAD

Nov -16

Source: defenseworld.net

Atria Investments Inc Boosts Holdings in ACADIA Pharmaceuticals Inc. $ACAD

Nov -11

Source: defenseworld.net

ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov -10

Source: seekingalpha.com

ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth

Nov -06

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (13.00%)

6. Segments

Innovative Medicines

Expected Growth: 13%

ACADIA Pharmaceuticals Inc.'s Innovative Medicines segment growth is driven by increasing adoption of pimavanserin, a novel treatment for Parkinson's disease psychosis, and strong sales of trofinetide, a potential therapy for Rett syndrome. Additionally, the company's robust pipeline, including candidates for major depressive disorder and Alzheimer's disease, contributes to its growth momentum.

7. Detailed Products

NUPLAZID

NUPLAZID (pimavanserin) is a selective serotonin inverse agonist indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Trofinetide

Trofinetide is a novel, oral, phosphorylated trophin-like molecule being developed for the treatment of Rett syndrome, a rare genetic disorder.

8. ACADIA Pharmaceuticals Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

ACADIA Pharmaceuticals Inc. has a moderate threat of substitutes due to the availability of alternative treatments for central nervous system disorders.

Bargaining Power Of Customers

ACADIA Pharmaceuticals Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the complexity of the pharmaceutical supply chain.

Bargaining Power Of Suppliers

ACADIA Pharmaceuticals Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and the company's dependence on these suppliers.

Threat Of New Entrants

ACADIA Pharmaceuticals Inc. has a high threat of new entrants due to the attractiveness of the pharmaceutical industry and the potential for new companies to enter the market.

Intensity Of Rivalry

ACADIA Pharmaceuticals Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	11.70%
Debt Cost	3.95%
Equity Weight	88.30%
Equity Cost	5.84%
WACC	5.62%
Leverage	13.25%

11. Quality Control: ACADIA Pharmaceuticals Inc. passed 5 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Inefficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

ACADIA Pharmaceuticals

A-Score: 5.6/10

Value: 3.0

Growth: 9.0

Quality: 9.1

Yield: 0.0

Momentum: 9.0

Volatility: 3.3

1-Year Total Return ->

TG Therapeutics

A-Score: 4.8/10

Value: 2.0

Growth: 8.2

Quality: 7.7

Yield: 0.0

Momentum: 8.5

Volatility: 2.7

1-Year Total Return ->

Arrowhead Pharmaceuticals

A-Score: 3.9/10

Value: 6.2

Growth: 1.1

Quality: 4.2

Yield: 0.0

Momentum: 10.0

Volatility: 2.0

1-Year Total Return ->

Janux Therapeutics

A-Score: 3.8/10

Value: 9.0

Growth: 3.4

Quality: 7.9

Yield: 0.0

Momentum: 1.0

Volatility: 1.3

1-Year Total Return ->

Geron

A-Score: 3.1/10

Value: 7.0

Growth: 5.3

Quality: 4.8

Yield: 0.0

Momentum: 0.0

Volatility: 1.7

1-Year Total Return ->

Ultragenyx Pharmaceutical

A-Score: 3.0/10

Value: 6.4

Growth: 4.7

Quality: 3.5

Yield: 0.0

Momentum: 0.0

Volatility: 3.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

0.80%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

5.62%

ACADIA Pharmaceuticals Inc. - US0042251084

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on ACAD

1.c. Company Highlights

Expensive

Higher Growth

Stable Momentum

Earnings Beats

Revenues Miss

Weak Momentum

Revenues Beats

Better Quality

Strong Momentum

2. ACADIA Pharmaceuticals' Q3 2025 Earnings: Strong Revenue Growth and Pipeline Advancements

Revenue Breakdown and Guidance Update

Pipeline Advancements and Future Growth

Valuation and Growth Prospects

Commercial Strategy and Investment

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (13.00%)

6. Segments

Innovative Medicines

Expected Growth: 13%

7. Detailed Products

NUPLAZID

Trofinetide

8. ACADIA Pharmaceuticals Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: ACADIA Pharmaceuticals Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

27.44$

Current Price

27.44$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA